Sun Pharma Advanced Research Co Ltd
NSE:SPARC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sun Pharma Advanced Research Co Ltd
Operating Income
Sun Pharma Advanced Research Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sun Pharma Advanced Research Co Ltd
NSE:SPARC
|
Operating Income
-₹2.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-13%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Income
₹63.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Operating Income
₹53.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Operating Income
₹135.6B
|
CAGR 3-Years
42%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Operating Income
₹59.6B
|
CAGR 3-Years
147%
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Income
₹33.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
Sun Pharma Advanced Research Co Ltd
Glance View
Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-07-18. The firm is engaged in the business of research and development (R&D) of pharmaceutical products to meet unmet medical needs in the areas of oncology, neurodegeneration and immunology. The company develops new chemical entities (NCE), new biological entities (NDDS) and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its NDDS includes Wrap Matrix technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology, which is useful to develop controlled-release tablets. The firm has developed Elepsia XR, using Wrap Matrix technology. Lipexelle technology for ophthalmic formulations. The company has developed Xelpros, a BAK-free latanoprost eye drops developed using Lipexelle technology. Xelpros is commercialized by the Company’s partner in the United States. The company developed PDP-716 eye drops for the treatment of glaucoma based on its TearAct technology.
See Also
What is Sun Pharma Advanced Research Co Ltd's Operating Income?
Operating Income
-2.4B
INR
Based on the financial report for Dec 31, 2025, Sun Pharma Advanced Research Co Ltd's Operating Income amounts to -2.4B INR.
What is Sun Pharma Advanced Research Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-13%
Over the last year, the Operating Income growth was 39%. The average annual Operating Income growth rates for Sun Pharma Advanced Research Co Ltd have been -6% over the past three years , -4% over the past five years , and -13% over the past ten years .
